PubMed:34047722 JSONTXT

{"project":"Inflammaging","denotations":[{"id":"T1","span":{"begin":0,"end":132},"obj":"Sentence"},{"id":"T2","span":{"begin":133,"end":163},"obj":"Sentence"},{"id":"T3","span":{"begin":164,"end":174},"obj":"Sentence"},{"id":"T4","span":{"begin":175,"end":337},"obj":"Sentence"},{"id":"T5","span":{"begin":338,"end":345},"obj":"Sentence"},{"id":"T6","span":{"begin":346,"end":385},"obj":"Sentence"},{"id":"T7","span":{"begin":386,"end":394},"obj":"Sentence"},{"id":"T8","span":{"begin":395,"end":451},"obj":"Sentence"},{"id":"T9","span":{"begin":452,"end":465},"obj":"Sentence"},{"id":"T10","span":{"begin":466,"end":517},"obj":"Sentence"},{"id":"T11","span":{"begin":518,"end":531},"obj":"Sentence"},{"id":"T12","span":{"begin":532,"end":668},"obj":"Sentence"},{"id":"T13","span":{"begin":669,"end":839},"obj":"Sentence"},{"id":"T14","span":{"begin":840,"end":848},"obj":"Sentence"},{"id":"T15","span":{"begin":849,"end":896},"obj":"Sentence"},{"id":"T16","span":{"begin":897,"end":1129},"obj":"Sentence"},{"id":"T17","span":{"begin":1130,"end":1138},"obj":"Sentence"},{"id":"T18","span":{"begin":1139,"end":1233},"obj":"Sentence"},{"id":"T19","span":{"begin":1234,"end":1409},"obj":"Sentence"},{"id":"T20","span":{"begin":1410,"end":1520},"obj":"Sentence"},{"id":"T21","span":{"begin":1521,"end":1670},"obj":"Sentence"},{"id":"T22","span":{"begin":1671,"end":1735},"obj":"Sentence"},{"id":"T23","span":{"begin":1736,"end":1884},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":132},"obj":"Sentence"},{"id":"T2","span":{"begin":133,"end":163},"obj":"Sentence"},{"id":"T3","span":{"begin":164,"end":174},"obj":"Sentence"},{"id":"T4","span":{"begin":175,"end":337},"obj":"Sentence"},{"id":"T5","span":{"begin":338,"end":345},"obj":"Sentence"},{"id":"T6","span":{"begin":346,"end":385},"obj":"Sentence"},{"id":"T7","span":{"begin":386,"end":394},"obj":"Sentence"},{"id":"T8","span":{"begin":395,"end":451},"obj":"Sentence"},{"id":"T9","span":{"begin":452,"end":465},"obj":"Sentence"},{"id":"T10","span":{"begin":466,"end":517},"obj":"Sentence"},{"id":"T11","span":{"begin":518,"end":531},"obj":"Sentence"},{"id":"T12","span":{"begin":532,"end":668},"obj":"Sentence"},{"id":"T13","span":{"begin":669,"end":839},"obj":"Sentence"},{"id":"T14","span":{"begin":840,"end":848},"obj":"Sentence"},{"id":"T15","span":{"begin":849,"end":896},"obj":"Sentence"},{"id":"T16","span":{"begin":897,"end":1129},"obj":"Sentence"},{"id":"T17","span":{"begin":1130,"end":1138},"obj":"Sentence"},{"id":"T18","span":{"begin":1139,"end":1233},"obj":"Sentence"},{"id":"T19","span":{"begin":1234,"end":1409},"obj":"Sentence"},{"id":"T20","span":{"begin":1410,"end":1520},"obj":"Sentence"},{"id":"T21","span":{"begin":1521,"end":1670},"obj":"Sentence"},{"id":"T22","span":{"begin":1671,"end":1735},"obj":"Sentence"},{"id":"T23","span":{"begin":1736,"end":1884},"obj":"Sentence"}],"text":"Early Goal-Directed Therapy With and Without Intermittent Superior Vena Cava Oxygen Saturation Monitoring in Pediatric Septic Shock: A Randomized Controlled Trial.\nOBJECTIVE: To compare early goal-directed therapy (EGDT) 'with' and 'without' intermittent superior vena cava oxygen saturation (ScvO2) monitoring in pediatric septic shock.\nDESIGN: Open label randomized controlled trial.\nSETTING: Pediatric intensive care unit in a tertiary care center.\nPARTICIPANTS: Children aged 1 month to 12 year with septic shock.\nINTERVENTION: Patients not responding to fluid resuscitation (up to 40 mL/kg) were randomized to EGDT 'with' (n=59) and 'without' (n=61) ScvO2 groups. Resuscitation was guided by ScvO2 monitoring at 1-hour, 3-hour, and later on six-hourly in the 'with' ScvO2 group, and by clinical variables in the 'without' ScvO2 group.\nOUTCOME: Primary outcome was all-cause 28-day mortality. Secondary outcomes were time to and proportion of patients achieving therapeutic endpoints (at 6 hours and PICU stay), need for organ supports, new organ dysfunction (at 24 hours and PICU stay), and length of PICU and hospital stay.\nRESULTS: The study was stopped after interim analysis due to lower mortality in the intervention group. There was significantly lower all-cause 28-day mortality in EDGT with ScvO2 than without ScvO2 group [37.3% vs. 57.5%, adjusted hazard ratio 0.57, 95%CI 0.33 to 0.97, P=0.04]. Therapeutic endpoints were achieved early in 'with' ScvO2 group [mean (SD) 3.6 (1.6) vs. 4.2 (1.6) h, P=0.03]. Organ dysfunction by sequential organ assessment score during PICU stay was lower in 'with' ScvO2 group [median (IQR) 5 (2,11) vs. 8 (3,13); P=0.03]. There was no significant difference in other secondary outcomes.\nCONCLUSIONS: EGDT with intermittent ScvO2 monitoring was associated with reduced mortality and improved organ dysfunction in pediatric septic shock."}

{"project":"chenxin_473849_800_3","denotations":[{"id":"T1","span":{"begin":504,"end":516},"obj":"DP"},{"id":"T2","span":{"begin":324,"end":336},"obj":"DP"},{"id":"T3","span":{"begin":1871,"end":1883},"obj":"DP"},{"id":"T4","span":{"begin":119,"end":131},"obj":"DP"}],"text":"Early Goal-Directed Therapy With and Without Intermittent Superior Vena Cava Oxygen Saturation Monitoring in Pediatric Septic Shock: A Randomized Controlled Trial.\nOBJECTIVE: To compare early goal-directed therapy (EGDT) 'with' and 'without' intermittent superior vena cava oxygen saturation (ScvO2) monitoring in pediatric septic shock.\nDESIGN: Open label randomized controlled trial.\nSETTING: Pediatric intensive care unit in a tertiary care center.\nPARTICIPANTS: Children aged 1 month to 12 year with septic shock.\nINTERVENTION: Patients not responding to fluid resuscitation (up to 40 mL/kg) were randomized to EGDT 'with' (n=59) and 'without' (n=61) ScvO2 groups. Resuscitation was guided by ScvO2 monitoring at 1-hour, 3-hour, and later on six-hourly in the 'with' ScvO2 group, and by clinical variables in the 'without' ScvO2 group.\nOUTCOME: Primary outcome was all-cause 28-day mortality. Secondary outcomes were time to and proportion of patients achieving therapeutic endpoints (at 6 hours and PICU stay), need for organ supports, new organ dysfunction (at 24 hours and PICU stay), and length of PICU and hospital stay.\nRESULTS: The study was stopped after interim analysis due to lower mortality in the intervention group. There was significantly lower all-cause 28-day mortality in EDGT with ScvO2 than without ScvO2 group [37.3% vs. 57.5%, adjusted hazard ratio 0.57, 95%CI 0.33 to 0.97, P=0.04]. Therapeutic endpoints were achieved early in 'with' ScvO2 group [mean (SD) 3.6 (1.6) vs. 4.2 (1.6) h, P=0.03]. Organ dysfunction by sequential organ assessment score during PICU stay was lower in 'with' ScvO2 group [median (IQR) 5 (2,11) vs. 8 (3,13); P=0.03]. There was no significant difference in other secondary outcomes.\nCONCLUSIONS: EGDT with intermittent ScvO2 monitoring was associated with reduced mortality and improved organ dysfunction in pediatric septic shock."}

{"project":"yangbin123xm_800_3","denotations":[{"id":"T1","span":{"begin":119,"end":131},"obj":"DP"},{"id":"T2","span":{"begin":324,"end":336},"obj":"DP"},{"id":"T3","span":{"begin":504,"end":516},"obj":"DP"},{"id":"T4","span":{"begin":1871,"end":1883},"obj":"DP"}],"text":"Early Goal-Directed Therapy With and Without Intermittent Superior Vena Cava Oxygen Saturation Monitoring in Pediatric Septic Shock: A Randomized Controlled Trial.\nOBJECTIVE: To compare early goal-directed therapy (EGDT) 'with' and 'without' intermittent superior vena cava oxygen saturation (ScvO2) monitoring in pediatric septic shock.\nDESIGN: Open label randomized controlled trial.\nSETTING: Pediatric intensive care unit in a tertiary care center.\nPARTICIPANTS: Children aged 1 month to 12 year with septic shock.\nINTERVENTION: Patients not responding to fluid resuscitation (up to 40 mL/kg) were randomized to EGDT 'with' (n=59) and 'without' (n=61) ScvO2 groups. Resuscitation was guided by ScvO2 monitoring at 1-hour, 3-hour, and later on six-hourly in the 'with' ScvO2 group, and by clinical variables in the 'without' ScvO2 group.\nOUTCOME: Primary outcome was all-cause 28-day mortality. Secondary outcomes were time to and proportion of patients achieving therapeutic endpoints (at 6 hours and PICU stay), need for organ supports, new organ dysfunction (at 24 hours and PICU stay), and length of PICU and hospital stay.\nRESULTS: The study was stopped after interim analysis due to lower mortality in the intervention group. There was significantly lower all-cause 28-day mortality in EDGT with ScvO2 than without ScvO2 group [37.3% vs. 57.5%, adjusted hazard ratio 0.57, 95%CI 0.33 to 0.97, P=0.04]. Therapeutic endpoints were achieved early in 'with' ScvO2 group [mean (SD) 3.6 (1.6) vs. 4.2 (1.6) h, P=0.03]. Organ dysfunction by sequential organ assessment score during PICU stay was lower in 'with' ScvO2 group [median (IQR) 5 (2,11) vs. 8 (3,13); P=0.03]. There was no significant difference in other secondary outcomes.\nCONCLUSIONS: EGDT with intermittent ScvO2 monitoring was associated with reduced mortality and improved organ dysfunction in pediatric septic shock."}